Pro Share Advisors LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 35,325 shares of ARWR stock, worth $669,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,325
Previous 29,081 21.47%
Holding current value
$669,762
Previous $755,000 9.54%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$19.36 - $29.54 $120,883 - $184,447
6,244 Added 21.47%
35,325 $683,000
Q2 2024

Aug 13, 2024
SELL
$21.87 - $28.24 $142,395 - $183,870
-6,511 Reduced 18.29%
29,081 $755,000
Q1 2024

May 08, 2024
BUY
$27.21 - $39.48 $172,538 - $250,342
6,341 Added 21.68%
35,592 $1.02 Million
Q4 2023

Feb 14, 2024
BUY
$21.2 - $31.03 $70,129 - $102,647
3,308 Added 12.75%
29,251 $895,000
Q3 2023

Nov 13, 2023
SELL
$26.2 - $36.08 $14,488 - $19,952
-553 Reduced 2.09%
25,943 $697,000
Q2 2023

Aug 10, 2023
BUY
$25.16 - $41.38 $10,768 - $17,710
428 Added 1.64%
26,496 $944,000
Q1 2023

May 11, 2023
SELL
$23.68 - $38.51 $96,543 - $157,005
-4,077 Reduced 13.52%
26,068 $662,000
Q4 2022

Feb 02, 2023
BUY
$28.0 - $40.56 $67,872 - $98,317
2,424 Added 8.74%
30,145 $1.22 Million
Q3 2022

Nov 04, 2022
BUY
$29.63 - $48.31 $11,377 - $18,551
384 Added 1.4%
27,721 $917,000
Q2 2022

Aug 01, 2022
SELL
$27.79 - $50.61 $370,190 - $674,175
-13,321 Reduced 32.76%
27,337 $962,000
Q1 2022

May 10, 2022
SELL
$39.62 - $69.97 $326,310 - $576,272
-8,236 Reduced 16.84%
40,658 $1.87 Million
Q4 2021

Feb 08, 2022
BUY
$58.09 - $82.51 $230,675 - $327,647
3,971 Added 8.84%
48,894 $3.24 Million
Q3 2021

Nov 12, 2021
SELL
$58.38 - $84.96 $463,420 - $674,412
-7,938 Reduced 15.02%
44,923 $2.81 Million
Q2 2021

Aug 13, 2021
BUY
$62.15 - $90.32 $194,529 - $282,701
3,130 Added 6.29%
52,861 $4.38 Million
Q1 2021

May 14, 2021
BUY
$61.35 - $90.47 $220,123 - $324,606
3,588 Added 7.78%
49,731 $3.3 Million
Q4 2020

Feb 09, 2021
BUY
$43.82 - $85.37 $457,962 - $892,201
10,451 Added 29.28%
46,143 $3.54 Million
Q3 2020

Nov 13, 2020
SELL
$33.21 - $51.27 $31,449 - $48,552
-947 Reduced 2.58%
35,692 $1.54 Million
Q2 2020

Aug 03, 2020
BUY
$26.12 - $43.27 $363,825 - $602,707
13,929 Added 61.33%
36,639 $1.58 Million
Q1 2020

May 15, 2020
SELL
$20.56 - $63.12 $393,210 - $1.21 Million
-19,125 Reduced 45.72%
22,710 $653,000
Q4 2019

Feb 12, 2020
BUY
$28.14 - $73.01 $84,166 - $218,372
2,991 Added 7.7%
41,835 $2.65 Million
Q3 2019

Nov 12, 2019
SELL
$26.26 - $34.86 $38,575 - $51,209
-1,469 Reduced 3.64%
38,844 $1.1 Million
Q2 2019

Aug 13, 2019
SELL
$17.43 - $28.82 $32,681 - $54,037
-1,875 Reduced 4.44%
40,313 $1.07 Million
Q1 2019

May 15, 2019
BUY
$12.05 - $20.18 $38,355 - $64,232
3,183 Added 8.16%
42,188 $774,000
Q4 2018

Feb 14, 2019
SELL
$10.74 - $19.7 $80,947 - $148,478
-7,537 Reduced 16.19%
39,005 $484,000
Q3 2018

Nov 14, 2018
SELL
$14.0 - $20.3 $24,234 - $35,139
-1,731 Reduced 3.59%
46,542 $892,000
Q2 2018

Aug 13, 2018
BUY
$6.37 - $14.02 $51,890 - $114,206
8,146 Added 20.3%
48,273 $657,000
Q1 2018

May 14, 2018
SELL
$3.72 - $7.64 $576 - $1,184
-155 Reduced 0.38%
40,127 $289,000
Q4 2017

Feb 14, 2018
SELL
$3.14 - $4.5 $5,752 - $8,244
-1,832 Reduced 4.35%
40,282 $148,000
Q3 2017

Nov 13, 2017
BUY
$1.69 - $4.33 $6,310 - $16,168
3,734 Added 9.73%
42,114 $182,000
Q2 2017

Aug 11, 2017
BUY
N/A
38,380
38,380 $62,000

Others Institutions Holding ARWR

# of Institutions
294
Shares Held
90.8M
Call Options Held
155K
Put Options Held
426K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email